Peter Rhode - 14 Jan 2022 Form 4 Insider Report for HCW Biologics Inc. (HCWB)

Role
Title of the Officer: Chief Scientific Officer and Vice President of Clinical Operations.
Signature
/s/ Nicole Valdivieso, as Attorney-in-Fact for Peter Rhode
Issuer symbol
HCWB
Transactions as of
14 Jan 2022
Net transactions value
+$360
Form type
4
Filing time
19 Jan 2022, 16:42:09 UTC
Previous filing
10 Sep 2021
Next filing
20 Nov 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HCWB Common Stock Options Exercise $360 +1,714 +3.7% $0.2100* 48,499 14 Jan 2022 Direct
transaction HCWB Common Stock Options Exercise $0.14 +1 +0% $0.1400* 48,500 14 Jan 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HCWB Stock Option Grant (Right to Buy) Options Exercise $0 -1,714 -20% $0.000000 6,857 14 Jan 2022 Common Stock 1,714 $0.2100 Direct F1
transaction HCWB Stock Option Grant (Right to Buy) Options Exercise $0 -1 -0% $0.000000 51,427 14 Jan 2022 Common Stock 1 $0.1400 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 20% of the total shares subject to the stock option grant vested on December 22, 2021; 20% of the total shares subject to the stock option grant will vest on December 22, 2022; 25% of the total shares subject to the stock option grant will vest on December 22, 2023; and 35% of the total shares subject to the stock option grant will vest on December 22, 2024, subject to the reporting person's continuous service through the applicable vesting date.
F2 These option shares were part of a stock option grant covering 85,713 shares of common stock. 20% of the total shares subject to the stock option grant vested on May 30, 2020; 20% of the total shares subject to the stock option grant vested on May 30, 2021; 25% of the total shares subject to the stock option grant will vest on May 30, 2022; and 35% of the total shares subject to the stock option grant will vest on May 30, 2023, subject to the reporting person's continuous service through the applicable vesting date.

Remarks:

Title of the Officer: Chief Scientific Officer and Vice President of Clinical Operations.